Recent Advancements in CT and MR Imaging of Prostate Cancer

Daryanani, Asha; Türkbey, Barış

doi:10.1053/j.semnuclmed.2021.11.013

Cited by 12 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its utility in diagnosing prostate cancer has mostly been examined for its capacity to identify lymph node metastases, with mixed findings. Nevertheless, its application in high-risk prostate cancer has shown a noticeably enhanced specificity and sensitivity, indicating that it may be helpful in these circumstances for the identification of nodal metastases ( 111 ). It is uncertain, that whether choline PET-CT will play a part in the future of prostate cancer diagnostics given the advancements in 68Gallium (68Ga) labelled prostate specific membrane antigen PET-CT.…”

Section: Diagnostics For Prostate Cancermentioning

confidence: 99%

RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics

Thakur,

Quazi,

Naik

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Prostate adenocarcinoma accounts for more than 20% of deaths among males due to cancer. It is the fifth-leading cancer diagnosed in males across the globe. The mortality rate is quite high due to prostate cancer. Despite the fact that advancements in diagnostics and therapeutics have been made, there is a lack of effective drugs. Metabolic pathways are altered due to the triggering of androgen receptor (AR) signaling pathways, and elevated levels of dihydrotestosterone are produced due to defects in AR signaling that accelerate the growth of prostate cancer cells. Further, PI3K/AKT/mTOR pathways interact with AR signaling pathway and act as precursors to promote prostate cancer. Prostate cancer therapy has been classified into luminal A, luminal B, and basal subtypes. Therapeutic drugs inhibiting dihydrotestosterone and PI3K have shown to give promising results to combat prostate cancer. Many second-generation Androgen receptor signaling antagonists are given either as single agent or with the combination of other drugs. In order to develop a cure for metastasized prostate cancer cells, Androgen deprivation therapy (ADT) is applied by using surgical or chemical methods. In many cases, Prostatectomy or local radiotherapy are used to control metastasized prostate cancer. However, it has been observed that after 1.5 years to 2 years of Prostatectomy or castration, there is reoccurrence of prostate cancer and high incidence of castration resistant prostate cancer is seen in population undergone ADT. It has been observed that Androgen derivation therapy combined with drugs like abiraterone acetate or docetaxel improve overall survival rate in metastatic hormone sensitive prostate cancer (mHSPC) patients. Scientific investigations have revealed that drugs inhibiting poly ADP Ribose polymerase (PARP) are showing promising results in clinical trials in the prostate cancer population with mCRPC and DNA repair abnormalities. Recently, RISUG adv (reversible inhibition of sperm under guidance) has shown significant results against prostate cancer cell lines and MTT assay has validated substantial effects of this drug against PC3 cell lines. Current review paper highlights the advancements in prostate cancer therapeutics and new drug molecules against prostate cancer. It will provide detailed insights on the signaling pathways which need to be targeted to combat metastasized prostate cancer and castration resistant prostate cancer.

show abstract

Section: Diagnostics For Prostate Cancermentioning

confidence: 99%

RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics

Thakur,

Quazi,

Naik

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Future studies should employ additional imaging techniques to assess LNI. For example, dual-energy computed tomography may improve tissue characterization and the detection of subtle changes in lymph nodes [50].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Multiparametric MRI, [68Ga]Ga-PSMA-11 PET-CT, and Clinical Nomograms for Primary T and N Staging of Intermediate-to-High-Risk Prostate Cancer

Tayara,

Pełka,

Kunikowska

et al. 2023

Cancers

View full text Add to dashboard Cite

Purpose of the Report: Although multiparametric magnetic resonance imaging (mpMRI) is commonly used for the primary staging of prostate cancer, it may miss non-enlarged metastatic lymph nodes. Positron emission tomography-computed tomography targeting the prostate-specific membrane antigen (PSMA PET-CT) is a promising method to detect non-enlarged metastatic lymph nodes, but more data are needed. Materials and Methods: In this single-center, prospective study, we enrolled patients with intermediate-to-high-risk prostate cancer scheduled for radical prostatectomy with pelvic node dissection. Before surgery, prostate imaging with mpMRI and PSMA PET-CT was used to assess lymph node involvement (LNI), extra-prostatic extension (EPE), and seminal vesicle involvement (SVI). Additionally, we used clinical nomograms to estimate the risk of these three outcomes. Results: Of the 74 patients included, 61 (82%) had high-risk prostate cancer, and the rest had intermediate-risk cancer. Histopathology revealed LNI in 20 (27%) patients, SVI in 26 (35%), and EPE in 52 (70%). PSMA PET-CT performed better than mpMRI at detecting LNI (area under the curve (AUC, 95% confidence interval): 0.779 (0.665–0.893) vs. 0.655 (0.529–0.780)), but mpMRI was better at detecting SVI (AUC: 0.775 (0.672–0.878) vs. 0.585 (0.473–0.698)). The MSKCC nomogram performed well at detecting both LNI (AUC: 0.799 (0.680–0.918)) and SVI (0.772 (0.659–0.885)). However, when the nomogram was used to derive binary diagnoses, decision curve analyses showed that the MSKCC nomogram provided less net benefit than mpMRI and PSMA PET-CT for detecting SVI and LNI, respectively. Conclusions: mpMRI and [68Ga]Ga-PSMA-11 PET-CT are complementary techniques to be used in conjunction for the primary T and N staging of prostate cancer.

show abstract

“…But these devices are generally expensive and hard to be integrated into a surgery. [8][9][10] Modern medical diagnoses still rely heavily on biopsy to acquire molecular-level information, but its promotion is limited to facility availability, cost, and time. Artificial Intelligence (AI) technique shows great potential to achieve tissue recognition from medical imaging when given basic anatomic information.…”

Section: Introductionmentioning

confidence: 99%

Piezoresistivity modeling of soft tissue electrical-mechanical properties: A validation study

Guo

et al. 2023

Proc Inst Mech Eng H

View full text Add to dashboard Cite

In general, the electrical property of soft tissues is sensitive to the force applied to their surface. To further study the relationship between the force and the electrical property of soft tissues, this paper attempts to investigate the effect of static and higher-order stresses on electrical properties. Overall, a practical experimental platform is designed to acquire the force information and the electrical property of soft tissues during a contact procedure, which is featured different compression stimuli, such as constant pressing force, constant pressing speed, and step-force compression, etc. Furthermore, the piezoresistive characteristic is innovatively introduced to model the mechanical-electrical properties of soft tissue. Finite Element Modeling (FEM) is adopted to fit the static piezoresistivity of the soft tissue. Finally, experimental studies were performed to demonstrate the effect of stress on the electrical properties and the feasibility of the proposed piezoresistive model to describe soft tissues’ mechanical and electrical properties.

show abstract

Recent Advancements in CT and MR Imaging of Prostate Cancer

Cited by 12 publications

References 40 publications

RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics

RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics

Comparison of Multiparametric MRI, [68Ga]Ga-PSMA-11 PET-CT, and Clinical Nomograms for Primary T and N Staging of Intermediate-to-High-Risk Prostate Cancer

Piezoresistivity modeling of soft tissue electrical-mechanical properties: A validation study

Contact Info

Product

Resources

About